SALV.L

SalvaRx Group Plc
SalvaRx Group plc - Suspension of Trading
9th July 2019, 06:30
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 8421E
SalvaRx Group plc
09 July 2019
 

9 July 2019

SalvaRx Group plc

("SalvaRx" or the "Company")

Suspension of Trading

SalvaRx announces that trading in the Company's ordinary shares on AIM will be suspended with effect from 7.30 a.m. today.

The suspension is due to the Company not having made an acquisition or acquisitions which would constitute a reverse takeover under AIM Rule 14 ("Reverse Takeover"), or having been re-admitted to trading on AIM as an investing company under the AIM Rules, on or before the date falling six months from the Company's Annual General Meeting when it was classified as an AIM Rule 15 cash shell.

Trading in the Company's ordinary shares will remain suspended until the completion of a Reverse Takeover, which requires the publication of an admission document and the approval of such a transaction at a general meeting of the Company, or the Company is re-admitted to trading on AIM as an investing company.  If no such transaction is completed within six months the Company's shares will be cancelled from trading on AIM pursuant to AIM Rule 41.

The Board continues to seek suitable opportunities for a Reverse Takeover and will make a further announcement at the appropriate time.

 

Enquiries

SalvaRx Group plc

Denham Eke

Tel: +44 (0) 01624 639396

SP Angel Corporate Finance LLP

Nominated Adviser and Broker

Matthew Johnson / Jamie Spotswood (Corporate Finance)

Abigail Wayne (Corporate Broking)

Tel: +44 (0) 20 3470 0470

Peterhouse Corporate Finance Limited

Joint Broker

Lucy Williams / Duncan Vasey

Tel: +44 (0) 20 7469 0932

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
SRSUGUCWMUPBGCR ]]>
TwitterFacebookLinkedIn